Mimi Lee, M.D., Ph.D.

Dr. Mimi Lee is a physician-scientist, neurosurgeon, and anesthesiology who joined ARPA-H in July 2024. Lee is an executive leader in precision genetic medicines and rare diseases, bridging science, medicine, and business to realize high-impact innovations designed to improve lives. She has deep expertise spanning academic and community clinical research and practice, biotechnology, and innovative genetic medicines development and has led global cross-functional, multi-disciplinary teams bringing novel genetic medicines through R&D into commercialization. Her passion is co-designing with patients who bring a sense of urgency and respect scientific rigor to drive transformations through public-private partnerships. 

Lee’s portfolio focuses on accelerating the future of individualized, precision medicines with potential to predict, prevent, and cure. She has parallel interests in neurotechnology especially that designed to precisely detect, monitor, and perturb neural networks from systems down to cellular and genetic levels to address mental conditions that result in internal suffering. She has served in global leadership roles at BioMarin, Novartis, and Samsung, and holds a MD-PhD from the Albert Einstein College of Medicine, Certificates in Bioethics from Columbia and in Psychedelic-Assisted Therapies from the California Institute of Integral Studies. She completed three years of neurosurgical training at Barnes-Jewish Hospital at the Washington University in St. Louis and in anesthesiology at the University of California in San Francisco.